|
1Â
|
Vogl UM, Zehetgruber H, Dominkus M, et al:
Prognostic factors in metastatic renal cell carcinoma:
metastatectomy as independent prognostic variable. Br J Cancer.
95:691–698. 2006.
|
|
2Â
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. New Engl J Med. 356:115–124. 2007.
|
|
3Â
|
Motzer RJ, Escudier B, Oudard S, et al:
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomized, placebo-controlled phase III trial.
Lancet. 372:449–456. 2008.
|
|
4Â
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007.
|
|
5Â
|
Uemura H, Shinohara N, Yuasa T, et al: A
phase II study of sunitinib in Japanese patients with metastatic
renal cell carcinoma: insights into the treatment, efficacy and
safety. Jpn J Clin Oncol. 40:194–202. 2010.
|
|
6Â
|
Tomita Y, Shinohara N, Yuasa T, et al:
Overall survival and updated results from a phase II study of
sunitinib in Japanese patients with metastatic renal cell
carcinoma. Jpn J Clin Oncol. 40:1166–1172. 2010.
|
|
7Â
|
Akaza H, Tsukamoto T, Murai M, Nakajima K
and Naito S: Phase II study to investigate the efficacy, safety,
and pharmacokinetics of sorafenib in Japanese patients with
advanced renal cell carcinoma. Jpn J Clin Oncol. 37:755–762.
2007.
|
|
8Â
|
Tsukamoto T, Shinohara N, Tsuchiya N, et
al: Phase III trial of everolimus in metastatic renal cell
carcinoma: subgroup analysis of Japanese patients from RECORD-1.
Jpn J Clin Oncol. 41:17–24. 2011.
|
|
9Â
|
Fujisaka Y, Yamada Y, Yamamoto N, et al: A
phase 1 clinical study of temsirolimus (CCI-779) in Japanese
patients with advanced solid tumors. Jpn J Clin Oncol. 40:732–738.
2010.
|
|
10Â
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999.
|
|
11Â
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002.
|
|
12Â
|
Mekhail TM, Abou-Jawde RM, Boumerhi G, et
al: Validation and extention of the Memorial Sloan-Kettering
prognostic factors model for survival in patients with previously
untreated metastatic renal cell carcinoma. J Clin Oncol.
23:832–841. 2005.
|
|
13Â
|
Naito S, Yamamoto N, Takayama T, et al:
Prognosis of Japanese metastatic renal cell carcinoma patients in
the cytokine era: a cooperative group report of 1463 patients. Eur
Urol. 57:317–325. 2010.
|
|
14Â
|
Wu Y, Fu X, Zhu X, et al: Prognostic role
of systemic inflammatory response in renal cell carcinoma: a
systemic review and meta-analysis. J Cancer Res Clin Oncol.
137:887–896. 2011.
|
|
15Â
|
Johnson TV, Abbasi A, Owen-Smith A, et al:
Absolute preoperative C-reactive protein predicts metastasis and
mortality in the first year following potentially curative
nephrectomy for clear cell renal cell carcinoma. J Urol.
183:480–485. 2010.
|
|
16Â
|
Komai Y, Saito K, Sakai K and Morimoto S:
Increased preoperative serum C-reactive protein level predicts a
poor prognosis in patients with localized renal cell carcinoma. BJU
Int. 99:77–80. 2006.
|
|
17Â
|
Saito K, Tatokoro M, Fujii Y, et al:
Impact of C-reactive protein kinetics on survival of patients with
metastatic renal cell carcinoma. Eur Urol. 55:1145–1153. 2009.
|
|
18Â
|
Saito K and Kihara K: C-reactive protein
as a biomarker for urological cancers. Nat Rev Urol. 8:659–666.
2011.
|
|
19Â
|
Patil S, Figlin RA, Hutson TE, et al:
Prognostic factors for progression-free and overall survival with
sunitinib targeted therapy and with cytokine as first-line therapy
in patients with metastatic renal cell carcinoma. Ann Oncol.
22:295–300. 2011.
|
|
20Â
|
Beuselinck B, Oudard S, Rixe O, et al:
Negative impact of bone metastasis on outcome in clear-cell renal
cell carcinoma treated with sunitinib. Ann Oncol. 22:794–800.
2011.
|
|
21Â
|
Choueiri TK, Xie W, Kollmannsberger C, et
al: The impact of cytoreductive nephrectomy on survival of patients
with metastatic renal cell carcinoma receiving vascular endothelial
growth factor targeted therapy. J Urol. 185:60–66. 2011.
|
|
22Â
|
Polcari AJ, Gorbonos A, Milner JE and
Flanigan RC: The role of cytoreductive nephrectomy in the era of
molecular targeted therapy. Int J Urol. 16:227–233. 2009.
|
|
23Â
|
Crispen PL and Blute ML: Role of
cytoreductive nephrectomy in the era of targeted therapy for renal
cell carcinoma. Curr Urol Rep. 13:38–46. 2012.
|
|
24Â
|
Heikkilä K, Ebrahim S and Lawlor DA: A
systemic review of the association between circulating
concentrations of C reactive protein and cancer. J Epidemiol
Community Health. 61:824–833. 2007.
|
|
25Â
|
Canna K, McMillan DC, McKee RF, McNicol
AM, Horgan PG and McArdle CS: Evaluation of a cumulative prognostic
score based on the systemic inflammatory response in patients
undergoing potentially curative surgery for colorectal cancer. Br J
Cancer. 90:1707–1709. 2004.
|
|
26Â
|
McKeown DJ, Brown DJ, Kelly A, Wallace AM
and McMillan DC: The relationship between circulating
concentrations of C-reactive protein, inflammatory cytokines and
cytokine receptors in patients with non-small-cell lung cancer. Br
J Cancer. 91:1993–1995. 2004.
|
|
27Â
|
Yoshida S, Saito K, Koga F, et al:
C-reactive protein level predicts prognosis in patients with
muscle-invasive bladder cancer treated with chemotherapy. BJU Int.
101:978–981. 2008.
|
|
28Â
|
Abramovitch R, Marikovsky M, Meir G and
Neeman M: Stimulation of tumour growth by wound-derived growth
factors. Br J Cancer. 79:1392–1398. 1999.
|
|
29Â
|
Miki S, Iwano M, Miki Y, et al:
Interleukin-6 (IL-6) functions as an in vitro autocrine growth
factor in renal cell carcinomas. FEBS Lett. 250:607–610. 1989.
|
